摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(2-甲氧基)苯腈 | 80407-66-5

中文名称
4-(2-甲氧基)苯腈
中文别名
4-(2-甲氧基乙氧基)苯甲腈
英文名称
4-(2-methoxyethoxy)benzonitrile
英文别名
4-(2-methoxy-ethoxy)-benzonitrile;4-(2-Methoxy-aethoxy)-benzonitril
4-(2-甲氧基)苯腈化学式
CAS
80407-66-5
化学式
C10H11NO2
mdl
MFCD09907643
分子量
177.203
InChiKey
SISNRWJOVBGIJH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    44-45℃
  • 沸点:
    307℃
  • 密度:
    1.09
  • 闪点:
    122℃

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    42.2
  • 氢给体数:
    0
  • 氢受体数:
    3

SDS

SDS:233d22f94f9f6ffb051928c144b646ca
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-(2-甲氧基)苯腈吡啶 、 ammonium sulfide 、 三乙胺 作用下, 以 为溶剂, 以64 %的产率得到4-(2-Methoxyethoxy)benzene-1-carbothioamide
    参考文献:
    名称:
    PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER
    摘要:
    Provided according to some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. Pharmaceutical compositions comprising the same and methods of use for treating cancer and inhibiting PRX3 are also provided.
    公开号:
    WO2024044744A2
  • 作为产物:
    参考文献:
    名称:
    91.抗结核化合物。第六部分 p-(ω-烷氧基烷氧基)-N-芳基苯甲m及其类似物
    摘要:
    DOI:
    10.1039/jr9500000459
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS<br/>[FR] COMPOSES HETEROCYCLIQUES UTILES EN TANT QU'ACTIVATEURS DE NURR-1
    申请人:NOVARTIS AG
    公开号:WO2004072050A1
    公开(公告)日:2004-08-26
    The present invention relates to compounds of formula (I) : wherein R1 is hydroxy, C1-4 alkoxy ,amino, C1-4 alkyl-amino, di C1-4 alkylamino , benzyloxy or C2-C7 alkanoyl, R2 is C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4 alkoxy, CF3, halogen, C1-4alkylamino, di C1-4alkylamino, di C1-4 alkylamino C1-4 alkoxy or N-C1-4 alkoxy C1-4 alkyl-N­-C1-4 alkylamino, N-C1-4 alkyl-piperazinyl, morpholinyl or pyrrolidinyl-C1-4 alkoxy, wherein the C1-4 alkyl radicals in R2 are optionally further substituted by C1-4 alkyl, halogen, cyano, amino, alkoxy or alkylthio, X is N or O, Y is N, O or CH, Z is N or CH, and W is N or CH, provided that (a) R1 is not hydroxy or C1-4 alkoxy when R2 is CF3, X is O, Y is CH, Z is N and W is CH, (b) R1 is not hydroxy or C1-4 alkoxy when R2 is CF3 or chloro, X is N, Y is O, Z is CH and W is CH, (c) R1 is not hydroxy when R2 is CF3, X is O, Y is N, Z is CH and W is CH and (d) X and Y are not simultaneously O, the salts thereof; their preparation, their use and pharmaceutical compositions containing them.
    本发明涉及以下化合物的公式(I):其中R1是羟基,C1-4烷氧基,氨基,C1-4烷基氨基,二甲基胺基,苄氧基或C2-C7烷酰基,R2是C1-4烷基,C1-4烷氧基,C1-4烷氧基C1-4烷氧基,CF3,卤素,C1-4烷基氨基,二C1-4烷基胺基,二C1-4烷基胺基C1-4烷氧基或N-C1-4烷氧基C1-4烷基-N-C1-4烷基胺基,N-C1-4烷基哌嗪基,吗啉基或吡咯啉基-C1-4烷氧基,其中R2中的C1-4烷基基团可以进一步被C1-4烷基,卤素,氰基,氨基,烷氧基或烷基硫基取代,X是N或O,Y是N,O或CH,Z是N或CH,W是N或CH,但前提是(a)当R2是CF3,X是O,Y是CH,Z是N,W是CH时,R1不是羟基或C1-4烷氧基,(b)当R2是CF3或氯时,X是N,Y是O,Z是CH,W是CH时,R1不是羟基或C1-4烷氧基,(c)当R2是CF3,X是O,Y是N,Z是CH,W是CH时,R1不是羟基,(d)X和Y不同时是O,以及它们的盐;它们的制备,其用途以及含有它们的药物组合物。
  • Heterocyclic compounds useful as nurr-1 activators
    申请人:Hintermann Samuel
    公开号:US20060089365A1
    公开(公告)日:2006-04-27
    The present invention relates to compounds of formula (I): wherein R 1 is hydroxy, C 1-4 alkoxy, amino, C 1-4 alkyl-amino, di C 1-4 alkylamino, benzyloxy or C 2 -C 7 alkanoyl, R 2 is C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkoxy C 1-4 alkoxy, CF 3 , halogen, C 1-4 alkylamino, di C 1-4 alkylamino, di C 1-4 alkylamino C 1-4 alkoxy or N—C 1-4 alkoxy C 1-4 alkyl-N—C 1-4 alkylamino, N—C 1-4 alkyl-piperazinyl, morpholinyl or pyrrolidinyl-C 1-4 alkoxy, wherein the C 1-4 alkyl radicals in R 2 are optionally further substituted by C 1-4 alkyl, halogen, cyano, amino, alkoxy or alkylthio, X is N or O, Y is N, O or CH, Z is N or CH, and W is N or CH, provided that (a) R 1 is not hydroxy or C 1-4 alkoxy when R 2 is CF 3 , X is O, Y is CH, Z is N and W is CH, (b) R 1 is not hydroxy or C 1-4 alkoxy when R 2 is CF 3 or chloro, X is N, Y is O, Z is CH and W is CH, (c) R 1 is not hydroxy when R 2 is CF 3 , X is O, Y is N, Z is CH and W is CH and (d) X and Y are not simultaneously O, the salts thereof; their preparation, their use and pharmaceutical compositions containing them.
    本发明涉及式(I)的化合物:其中R1为羟基、C1-4烷氧基、氨基、C1-4烷基氨基、二个C1-4烷基氨基、苄氧基或C2-C7烷酰基,R2为C1-4烷基、C1-4烷氧基、C1-4烷氧基C1-4烷氧基、CF3、卤素、C1-4烷基氨基、二个C1-4烷基氨基、二个C1-4烷基氨基C1-4烷氧基或N-C1-4烷氧基C1-4烷基-N-C1-4烷基氨基、N-C1-4烷基哌嗪基、吗啉基或吡咯烷基-C1-4烷氧基,其中R2中的C1-4烷基基团可以选择进一步取代为C1-4烷基、卤素、氰基、烷氧基或烷基硫醚,X为N或O,Y为N、O或CH,Z为N或CH,W为N或CH,条件是(a)当R2为CF3,X为O,Y为CH,Z为N,W为CH时,R1不是羟基或C1-4烷氧基,(b)当R2为CF3或氯时,X为N,Y为O,Z为CH,W为CH时,R1不是羟基或C1-4烷氧基,(c)当R2为CF3,X为O,Y为N,Z为CH,W为CH时,R1不是羟基,(d)X和Y不同时为O,以及它们的盐;它们的制备、使用以及含有它们的制药组合物。
  • 91. Antituberculous compounds. Part VI. p-(ω-Alkoxyalkoxy)-N-arylbenzamidines and analogues
    作者:F. C. Cooper、M. W. Partridge
    DOI:10.1039/jr9500000459
    日期:——
  • HETEROCYCLIC COMPOUNDS USEFUL AS NURR-1 ACTIVATORS
    申请人:Novartis AG
    公开号:EP1597243A1
    公开(公告)日:2005-11-23
  • RAPAMYCIN ANALOGS AND USES THEREOF
    申请人:Navitor Pharmaceuticals, Inc.
    公开号:US20210186935A1
    公开(公告)日:2021-06-24
    The present invention provides compounds, compositions thereof, and methods of using the same.
查看更多